BRIEF

on BIOSYNEX (EPA:ALBIO)

BIOSYNEX Obtains Its First CE Markings According to IVDR Regulations

Stock price chart of BIOSYNEX (EPA:ALBIO) showing fluctuations.

BIOSYNEX, specialist in rapid tests and molecular biology, announced that it had obtained its first CE markings according to the new IVDR regulations. This step marks a significant advance for the safety and effectiveness of in vitro diagnostic devices.

These markings concern Class B and C tests for the detection of infectious agents, including sexually transmitted agents, and a coagulation test developed by Avalun. Compliance with IVDR simplifies certification of similar products in the future.

Products not yet certified continue to operate under the previous Directive until 2027. Recent ISO certifications of BIOSYNEX's quality management system reinforce this regulatory compliance.

The American subsidiary Chembio Diagnostics also obtained CE IVDR marking for a rapid HIV detection test. This compliance and certifications are important competitive assets for BIOSYNEX in a strict regulatory environment.

R. P.

Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.

Click here to consult the press release on which this article is based

See all BIOSYNEX news